[go: up one dir, main page]

EA201890313A1 - Гуманизированные антитела к пироглутаматному варианту бета-амилоида - Google Patents

Гуманизированные антитела к пироглутаматному варианту бета-амилоида

Info

Publication number
EA201890313A1
EA201890313A1 EA201890313A EA201890313A EA201890313A1 EA 201890313 A1 EA201890313 A1 EA 201890313A1 EA 201890313 A EA201890313 A EA 201890313A EA 201890313 A EA201890313 A EA 201890313A EA 201890313 A1 EA201890313 A1 EA 201890313A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amyloid
beta
humanized antibodies
amyloidosis
pyroglutamate
Prior art date
Application number
EA201890313A
Other languages
English (en)
Other versions
EA038120B1 (ru
Inventor
Мартин Кляйншмидт
Енс-Ульрих Рафельд
Анке Пичотта
Штефан Шиллинг
Стивен Гиллис
Original Assignee
Пробайодраг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пробайодраг Аг filed Critical Пробайодраг Аг
Publication of EA201890313A1 publication Critical patent/EA201890313A1/ru
Publication of EA038120B1 publication Critical patent/EA038120B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)

Abstract

Настоящее изобретение относится к гуманизированным антителам, которые связываются с эпитопом на N-конце пироглутаматного варианта бета-амилоидного пептида (Aβ N3pE), и к профилактическому и терапевтическому лечению заболеваний и состояний, которые связаны с накоплением и отложением амилоидных пептидов, таких как амилоидоз, группа нарушений и аномалий, ассоциированных с пироглутаматным вариантом амилоидного пептида, таких как болезнь Альцгеймера, синдром Дауна, церебральная амилоидная ангиопатия и другие связанные аспекты. Более конкретно оно относится к применению гуманизированных моноклональных антител для связывания пироглутаматного варианта бета-амилоидного пептида в плазме крови, головном мозге и спинно-мозговой жидкости для предупреждения накопления или для регрессии отложения Aβ N3pE в головном мозге и в различных тканях на периферии и для облегчения состояния при амилоидозе. Кроме того, настоящее изобретение относится к диагностическим анализам для проведения диагностики амилоидоза с применением гуманизированных антител по настоящему изобретению.
EA201890313A 2015-07-16 2016-07-15 Гуманизированные антитела к пироглутаматному варианту бета-амилоида EA038120B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193356P 2015-07-16 2015-07-16
US201562209650P 2015-08-25 2015-08-25
PCT/EP2016/066924 WO2017009459A2 (en) 2015-07-16 2016-07-15 Humanized antibodies

Publications (2)

Publication Number Publication Date
EA201890313A1 true EA201890313A1 (ru) 2018-09-28
EA038120B1 EA038120B1 (ru) 2021-07-08

Family

ID=56411667

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890313A EA038120B1 (ru) 2015-07-16 2016-07-15 Гуманизированные антитела к пироглутаматному варианту бета-амилоида

Country Status (14)

Country Link
US (2) US10603367B2 (ru)
EP (1) EP3322723A2 (ru)
JP (2) JP7002811B2 (ru)
KR (1) KR102786380B1 (ru)
CN (1) CN108699139B (ru)
AU (1) AU2016293104B2 (ru)
BR (1) BR112018000097A2 (ru)
CA (1) CA2992386A1 (ru)
EA (1) EA038120B1 (ru)
IL (1) IL256579B2 (ru)
MX (1) MX2018000696A (ru)
NZ (1) NZ739181A (ru)
WO (1) WO2017009459A2 (ru)
ZA (1) ZA201800048B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
AU2019354714A1 (en) * 2018-10-04 2021-04-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Humanised anti-N-truncated amyloid beta monoclonal antibody
JP7617848B2 (ja) 2019-03-26 2025-01-20 ヤンセン ファーマシューティカ エヌ．ベー． ピログルタメートアミロイド－βに対する抗体及びその使用
WO2021005857A1 (ja) * 2019-07-05 2021-01-14 株式会社 島津製作所 アミロイドベータに対するモノクローナル抗体、及びその抗体を用いるアミロイドベータ関連ペプチドの測定方法
WO2021024209A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Inc. Antibodies that bind to pathological tau species and uses thereof
IL300059A (en) 2020-07-23 2023-03-01 Othair Prothena Ltd Anti-abeta antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
MX2024005072A (es) * 2021-10-28 2024-09-06 Abbvie Inc Anticuerpos anti-amiloide beta y métodos de uso de los mismos.
CN115354048B (zh) * 2022-06-08 2024-02-02 暨南大学 阿尔茨海默病动物模型的构建方法、用途和Aβ42重组表达载体
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058405B2 (en) * 2008-07-21 2011-11-15 Probiodrug (AG) Antibodies specific for N-terminal truncated and pyroglutamate modified amyloid-beta peptides
US20110002945A1 (en) * 2009-07-01 2011-01-06 O'nuallain Brian Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins
EP2603524A1 (en) * 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
KR102020072B1 (ko) * 2011-03-16 2019-11-04 프로비오드룩 아게 진단 항체 시험
US9499610B2 (en) * 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ

Also Published As

Publication number Publication date
US11045533B2 (en) 2021-06-29
KR102786380B1 (ko) 2025-03-26
IL256579A (en) 2018-02-28
US20180140689A1 (en) 2018-05-24
US20200138922A1 (en) 2020-05-07
IL256579B2 (en) 2023-03-01
WO2017009459A3 (en) 2017-03-16
EA038120B1 (ru) 2021-07-08
AU2016293104B2 (en) 2022-08-11
CN108699139B (zh) 2022-06-24
JP2022017271A (ja) 2022-01-25
IL256579B (en) 2022-11-01
AU2016293104A1 (en) 2018-02-08
ZA201800048B (en) 2018-11-28
WO2017009459A2 (en) 2017-01-19
JP2018524370A (ja) 2018-08-30
CN108699139A (zh) 2018-10-23
BR112018000097A2 (pt) 2018-09-04
MX2018000696A (es) 2018-05-28
CA2992386A1 (en) 2017-01-19
NZ739181A (en) 2023-05-26
JP7002811B2 (ja) 2022-03-04
US10603367B2 (en) 2020-03-31
EP3322723A2 (en) 2018-05-23
KR20180030653A (ko) 2018-03-23

Similar Documents

Publication Publication Date Title
EA201890313A1 (ru) Гуманизированные антитела к пироглутаматному варианту бета-амилоида
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EA201891286A1 (ru) АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
MX356800B (es) Anticuerpo tau humanizado.
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2012045882A3 (en) Phosphospecific antibodies recognising tau
CY1124563T1 (el) Βελτιωμενα antισωmata δεσμευσης πρωτοϊνιδιων α- βητα
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
NO20090156L (no) Humanisert antistoff
MX341369B (es) Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
WO2019098763A3 (ko) 알파-시누클레인에 대한 항체 및 그 용도
WO2009048539A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
EA201892690A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
MX2019015602A (es) Anticuerpos contra el beta-amiloide.
WO2014007982A3 (en) C-terminal and central epitope a-beta antibodies
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
CO6602134A2 (es) Proteinas de union a antigeno especificas para componente amiloide serico p
EA202091629A1 (ru) Гуманизированные и деиммунизированные антитела
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
PH12014502582A1 (en) Compounds
JP2009178162A5 (ru)
MY165105A (en) Humanized antibody against amyloid beta
EA201990559A1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title